Laura L. Holman

Obstetrics and Gynecology
800 NE 10th St Ste 2100
Oklahoma City, OK 73104

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 46 publications

Radiation Quality and Workflow in NRG GY017: Anti-PD-L1 (Atezolizumab) as an Immune Primer or Concurrently With Radiation Therapy for Node-Positive Locally Advanced Cervical Cancer.

Radiation Quality and Workflow in NRG GY017: Anti-PD-L1 (Atezolizumab) as an Immune Primer or Concurrently With Radiation Therapy for Node-Positive Locally Advanced Cervical Cancer.

Journal: International journal of radiation oncology, biology, physics
Published: January 12, 2026

Radiation Quality and Workflow in NRG GY017: Anti PD-L1 (Atezolizumab) as an immune primer or concurrently with RT for node positive locally advanced cervical cancer.

Radiation Quality and Workflow in NRG GY017: Anti PD-L1 (Atezolizumab) as an immune primer or concurrently with RT for node positive locally advanced cervical cancer.

Journal: International journal of radiation oncology, biology, physics
Published: January 12, 2026

Combined Urogynecology and Gynecologic Oncology Surgery Complications.

Combined Urogynecology and Gynecologic Oncology Surgery Complications.

Journal: Urogynecology (Philadelphia, Pa.)
Published: December 13, 2025

Phase II Trial of Ribociclib Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube, or Peritoneum: A GOG Partners Trial (GOG 3026).

Phase II Trial of Ribociclib Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube, or Peritoneum: A GOG Partners Trial (GOG 3026).

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 12, 2025

Patient-reported outcomes of a randomized phase III clinical trial of adjuvant radiation versus chemoradiation in intermediate risk, stage I/IIA cervical cancer patients treated with initial radical hysterectomy and pelvic lymphadenectomy (NRG/GOG-0263).

Patient-reported outcomes of a randomized phase III clinical trial of adjuvant radiation versus chemoradiation in intermediate risk, stage I/IIA cervical cancer patients treated with initial radical hysterectomy and pelvic lymphadenectomy (NRG/GOG-0263).

Journal: Gynecologic oncology
Published: August 11, 2025

Feasibility IB trial of paclitaxel/carboplatin + Galunisertib. (a small molecule inhibitor of the kinase domain of type 1 TGF-B receptor) in patients with newly diagnosed, persistent or recurrent carcinosarcoma of the uterus or ovary.

Feasibility IB trial of paclitaxel/carboplatin + Galunisertib. (a small molecule inhibitor of the kinase domain of type 1 TGF-B receptor) in patients with newly diagnosed, persistent or recurrent carcinosarcoma of the uterus or ovary.

Journal: Gynecologic oncology
Published: July 11, 2025

Germline POT1 Variants in a Pan-Cancer Cohort.

Germline POT1 Variants in a Pan-Cancer Cohort.

Journal: JCO precision oncology
Published: July 09, 2025

Image guided brachytherapy quality assurance on NRG GY017 investigating immunotherapy in addition to chemoradiation for locally advanced cervical cancer.

Image guided brachytherapy quality assurance on NRG GY017 investigating immunotherapy in addition to chemoradiation for locally advanced cervical cancer.

Journal: Brachytherapy
Published: April 04, 2025

Image guided brachytherapy quality assurance on NRG GY017 investigating immunotherapy in addition to chemoradiation for locally advanced cervical cancer.

Image guided brachytherapy quality assurance on NRG GY017 investigating immunotherapy in addition to chemoradiation for locally advanced cervical cancer.

Journal: Brachytherapy
Published: April 04, 2025

Evaluation of physical function and quality of life before and after nonradical surgical therapy for stage IA1 and IA2-IB1 cervical cancer (GOG-0278).

Evaluation of physical function and quality of life before and after nonradical surgical therapy for stage IA1 and IA2-IB1 cervical cancer (GOG-0278).

Journal: Gynecologic oncology
Published: January 10, 2025

Evaluation of efficacy and fertility after nonradical surgical therapy (extra fascial hysterectomy or cone biopsy, with pelvic lymphadenectomy) for stage IA1, IA2, and IB1 cervical cancer (GOG-0278).

Evaluation of efficacy and fertility after nonradical surgical therapy (extra fascial hysterectomy or cone biopsy, with pelvic lymphadenectomy) for stage IA1, IA2, and IB1 cervical cancer (GOG-0278).

Journal: Gynecologic oncology
Published: January 10, 2025

Incorporation of triapine (T) to cisplatin chemoradiation (CRT) for locally advanced cervical and vaginal cancer: Results from NRG-GY006, a phase III randomized trial.

Incorporation of triapine (T) to cisplatin chemoradiation (CRT) for locally advanced cervical and vaginal cancer: Results from NRG-GY006, a phase III randomized trial.

Journal: Gynecologic oncology
Published: January 05, 2025
Showing 1-12 of 46

Last Updated: 09/26/2026